Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Abstract Background Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as a prescreen for PARPi treatment and cancer predisposition testing. Methods Formalin-fixed paraffin-embedded tissue was obtained from OC patients in seven hospitals immediately after diagnosis or primary surgery. DNA was extracted, and universal tumor BRCA1/2 testing was then performed in a single site. Diagnostic yield, uptake, referral rates for genetic predisposition testing, and experiences of patients and gynecologists were evaluated. Results Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful. In 51 of these patients, pathogenic variants were detected (16.7%). Most patients (88.2%) went on to have a genetic predisposition test. BRCA1/2 pathogenic variants were shown to be hereditary in 56.8% and somatic in 43.2% of patients. Participating gynecologists and patients were overwhelmingly positive about the workflow. Conclusions Universal tumor BRCA1/2 testing in all newly diagnosed OC patients is feasible, effective, and appreciated by patients and gynecologists. Because many variants cannot be detected in DNA from blood, testing tumor DNA as the first step can double the identification rate of patients who stand to benefit most from PARP inhibitors.

[1]  R. Kim,et al.  Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer , 2018, Cancers.

[2]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[3]  C. V. van Asperen,et al.  Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. , 2018, The Journal of molecular diagnostics : JMD.

[4]  W. Meschino,et al.  Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap , 2018, Journal of Medical Genetics.

[5]  P. Simpson,et al.  Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer. , 2018, Gynecologic oncology.

[6]  J. Bakkum-Gamez,et al.  Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis. , 2018, Gynecologic oncology.

[7]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[8]  J. V. D. van der Giessen,et al.  Referral to cancer genetic counseling: do migrant status and patients’ educational background matter? , 2017, Journal of Community Genetics.

[9]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  C. Childers,et al.  National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Scott,et al.  Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. , 2017, Gynecologic oncology.

[12]  A. Hoischen,et al.  Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas , 2016, Human mutation.

[13]  D. Matei,et al.  Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer , 2016, British Journal of Cancer.

[14]  D. Matei,et al.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. , 2016, The Lancet. Oncology.

[15]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[16]  P. Manders,et al.  Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. , 2016, Gynecologic oncology.

[17]  C. V. van Asperen,et al.  Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. , 2016, European journal of cancer.

[18]  A. Howell,et al.  Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality , 2016, Hereditary cancer in clinical practice.

[19]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[20]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[21]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[22]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .